Applications of monoclonal antibodies and biotechnology products in the treatment of chronic inflammatory diseases;Aplicaciones de anticuerpos monoclonales y productos de biotecnología en el tratamiento de las enfermedades inflamatorias crónicas

Revista Clinica Espanola

Volumn 205, Issue 3, 2005, Pages 127-136

  Marenco de la Fuente, J L ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Crohn's disease; Psoriasis; Rheumatoid arthritis; Rheumatoid psoriasis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; BASILIXIMAB; CELL RECEPTOR; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ONERCEPT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 11; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; VISILIZUMAB;

ANAPHYLAXIS; APLASTIC ANEMIA; BIOTECHNOLOGY; BLOOD DYSCRASIA; CHRONIC INFLAMMATION; CROHN DISEASE; DEMYELINATION; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; DYSPNEA; HEART FAILURE; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; IMMUNE SYSTEM; INFECTION; LATENT VIRUS INFECTION; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; MEDIATOR; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; TACHYCARDIA; THORAX DISEASE; TUBERCULOSIS;

EID: 17444389280     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072971     Document Type: Review

References (51)

1. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30:1205-13.
2. Bruce Smith J, Haynes MK. Rheumatoid arthritis-A molecular understanding. Ann Intern Med. 2002;136:908-22.
3. Arend WP, Gabay C. Cytokines in the rheumatic diseases. Rheum Dis Clin N Am. 2004;30:41-67.
4. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307-10.
5. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-63.
6. Maini R. Infliximab treatment of rheumatoid arthritis. Rheum Dis Clin N Am. 2004;30:329-47.
7. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-602.
8. Mayordomo L, Marenco JL, Gómez-Mateos J, Rejón E. Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol. 2002;31:44-5.
9. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-104.
10. Marenco JL, Caragol I. Las terapias biológicas y las infecciones. Rev Esp Reumatol. 2003;1:49-58.
11. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitor may predispose to significant increase in tuberculosis risk: a multicenter active surveillance report. Arthritis Rheum. 2003;48:2085-91.
12. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-9.
13. Brown SL, Greene MH, Gerson SK, Edwards T, Braun MM. Tumor necrosis factor against therapy and lymphoma development. Arthritis Rheum. 2002;46:3151-8.
14. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of child-bearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol. 2003;30:241-6.
15. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807-11.
16. Suhler E, Smith JR, Lauer AK, Kurtz DE, Wertheim MS, Pickard TD, et al. A prospective trial of infliximab therapy for patients with refractory uveitis: interim analysis of safety and efficacy outcomes. Association for Research in Vision and Ophthalmology Annual Meeting 2004. [Internet. Cited April 15, 2004]. Abstract and Program Planner 2003. Disponible en http://www.arvo.org
17. Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-alpha. J Clin Invest. 2003;112:1589-96.
18. Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet disease. J Rheumatol. 2004;31: 1241-3.
19. Muñoz-Fernández S, Hidalgo V, Fernández MJ, Schlinker A, Martín Mola E. Effect of Infliximab an threatening panuveit is in Behçet disease [carta]. Lancet. 2001;358:1644.
20. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease [carta]. Ann Intern Med. 2004; 140:404-6.
21. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-8.
22. Mansour AM. Infliximab treatment of posterior uveitis [carta]. Ophthalmology. 2004;111:197-8.
23. Melikoglu M, Ozyazgan Y, Fresko I, et al. The response of treatment resistant uveitis in Behçet's syndrome (BS) to a TNF-alpha blocker, etanercept: an open study [abstract]. Arthritis Rheum. 2002;46 Suppl:S181.
24. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995;9:619-32.
25. Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin N Am. 2004;30:349-64.
26. Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995;34:334-42.
27. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford). 2002;41:1133-7.
28. Keystone EC, Schiff M, Kremer J, Fleischmann RM, Burge DJ. Once-weekly administration of 50 mg etanercept (enbrel) results of a phase III multicenter clinical trial. Ann Rheum Dis. 2003;62 Suppl 1:
29. Clunie G, Voules S, Watts R. Dose reduction of etanercept-can we treat more patients using a fixed budget? Rheumatology (Oxford). 2003;42:600-1.
30. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
31. Schwartzman S, Fleischmann R, Morgan GJ Jr. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther. 2004;6 Suppl 2:S3-11.
32. Genovese MC, Bathon JM, Martín RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis; two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443-50.
33. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-81.
34. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis. 2003;62:74-6.
35. Genovese MC, Kremel JM. Treatment of rheumatoid arthritis with etanercept. Rheum Dis Clin N Am. 2004;30:311-28.
36. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-5.
37. Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, et al. Pneumococcal vaccine responses in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004:31:1356-61.
38. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740-51.
39. Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther. 2003;17:185-92.
40. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761-9.
41. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004;126:989-96.
42. Cohen SB. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 2004; 30:365-80.
43. Bresnihan B, Álvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-204.
44. Zif MH, Keystone EC, Gibofsky A, Markenson JA, Weaver A, Whitmore J, et al. An evaluation of the use of anakinra by rheumatoid arthritis patients previously treated with a TNF inhibitor. Ann Rheum Dis. 2003; 62 Suppl 1: 186.
45. Kremer JM. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. Rheum Dis Clin N Am. 2004;30:381-91.
46. Edwards JC, Szczepanski L, Sczechincski J, Sosnowska AF, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81.
47. Edwards JCW, Leandro MJ, Cambridge G. B-lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin N Am. 2004; 30:393-403.
48. Taylor PC. Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Des. 2003;9:1095-106.
49. Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, et al. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res. 2001;3:247-52.
50. Lim WC, Hanauer SB. Emerging biologic therapies in inflammatory bowel disease reviews in gastroenterological disorders. 2004;4:61-85.
51. Haraoui B. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? J Rheumatol. 2004;31:1021-2.